Mirum Pharmaceuticals, Inc. reported total revenue of $111.6 million for the first quarter of 2025. This represents a substantial 61% increase compared to the same period in the previous year, driven by strong commercial execution.
Following this strong start to the year, Mirum increased its full-year 2025 net product sales guidance to a range of $435 million to $450 million. This updated outlook reflects the company's confidence in continued demand for its approved medicines.
LIVMARLI sales reached $73.2 million in Q1 2025, marking over 70% year-over-year growth, while the Bile Acid Medicines contributed $38.4 million, a 47% increase from Q1 2024. The company also noted that the VISTAS study in PSC is expected to complete enrollment in Q3 2025, with topline data anticipated in Q2 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.